Johnson & Johnson (J&J) is a major player in the healthcare and consumer goods industries, specializing in pharmaceuticals, medical equipment, and consumer health. Its shares are not directly listed on Indian stock exchanges such as the Bombay Stock Exchange (BSE) or the National Stock Exchange (NSE), but Indian investors can obtain them through American Depository Receipts (ADRs) or international brokerage accounts that allow trading on the New York Stock Exchange (NYSE), where J&J is traded under the ticker symbol JNJ. You can invest directly in Johnson & Johnson Share Price India 2025 India by https://www.indmoney.com/us-stocks.
You can invest directly in US stock by : https://www.indmoney.com/us-stocks
Johnson & Johnson Share Price India 2025 Overview
One of the biggest and most well-known healthcare corporations in the world, Johnson & Johnson (J&J), has been a major participant in the stock market for many years. J&J has continuously drawn investors looking for stability, growth, and long-term profits thanks to its innovative medical advancements and diverse portfolio that includes consumer health items, pharmaceuticals, and medical equipment. This Share analysis explores the historical performance of Johnson & Johnson Share Price India 2025, the reasons affecting its share price, and the things investors should know before adding this massive healthcare company to their portfolio.
A Brief Overview of Johnson & Johnson
Johnson & Johnson is a worldwide company that was founded in 1886 and produces a wide variety of goods. Three main business segments comprise the organization:
- Pharmaceuticals:The biggest source of income for J&J, providing therapies for illnesses in fields like neuroscience, immunology, and oncology.
- Medical Devices:A vast range of medical devices and instruments used in orthopedics, surgery, and other medical specialties are developed and produced by J&J.
- Consumer Health:This segment includes brands like Tylenol, Neutrogena, and Johnson’s Baby, catering to everyday health and wellness products.
J&J is regarded as a dependable stock for investors seeking exposure to the healthcare industry, which is renowned for its resilience and long-term growth potential, because of its wide diversification.
Valuation Measures
| Current | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|---|---|
| Market Cap | 373.28B | 390.12B | 351.76B | 381.20B | 377.32B | 375.05B |
| Enterprise Value | 388.73B | 406.13B | 359.17B | 387.61B | 383.73B | 392.15B |
| Trailing P/E | 25.63 | 24.52 | 21.72 | 30.42 | 29.41 | 31.59 |
| Forward P/E | 14.49 | 14.90 | 13.76 | 14.86 | 14.66 | 14.18 |
| PEG Ratio (5yr expected) | 0.92 | 0.95 | 0.88 | 0.97 | 1.65 | 5.14 |
| Price/Sales | 4.30 | 4.60 | 4.29 | 4.76 | 4.16 | 4.21 |
| Price/Book | 5.32 | 5.45 | 5.02 | 5.54 | 5.30 | 4.99 |
| Enterprise Value/Revenue | 4.43 | 4.69 | 4.19 | 4.55 | 3.89 | 4.36 |
| Enterprise Value/EBITDA | 15.14 | 14.75 | 12.74 | 16.62 | 15.56 | 24.98 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | 12/31/2023 |
| Most Recent Quarter (mrq) | 9/29/2024 |
Profitability
| Profit Margin | 16.74% |
| Operating Margin (ttm) | 24.52% |
Management Effectiveness
| Return on Assets (ttm) | 8.40% |
| Return on Equity (ttm) | 20.89% |
Income Statement
| Revenue (ttm) | 87.7B |
| Revenue Per Share (ttm) | 36.43 |
| Quarterly Revenue Growth (yoy) | 5.20% |
| Gross Profit (ttm) | — |
| EBITDA | 30.05B |
| Net Income Avi to Common (ttm) | 14.77B |
| Diluted EPS (ttm) | 6.05 |
| Quarterly Earnings Growth (yoy) | -89.70% |
Balance Sheet
| Total Cash (mrq) | 20.3B |
| Total Cash Per Share (mrq) | 8.43 |
| Total Debt (mrq) | 35.75B |
| Total Debt/Equity (mrq) | 50.96% |
| Current Ratio (mrq) | 1.03 |
| Book Value Per Share (mrq) | 29.14 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 25.15B |
| Levered Free Cash Flow (ttm) | 19.92B |
Abbreviation Guide
- mrq = Most Recent Quarter
- ttm = Trailing Twelve Months
- yoy = Year Over Year
- lfy = Last Fiscal Year
- fye = Fiscal Year Ending
Trading Information of Johnson & Johnson Share Price India 2025
Stock Price History
| Beta (5Y Monthly) | 0.52 |
| 52 Week Range 3 | 5.29% |
| S&P 500 52-Week Change 3 | 33.36% |
| 52 Week High 3 | 168.85 |
| 52 Week Low 3 | 143.13 |
| 50-Day Moving Average 3 | 162.61 |
| 200-Day Moving Average 3 | 156.06 |
Share Statistics
| Avg Vol (3 month) 3 | 6.1M |
| Avg Vol (10 day) 3 | 6.63M |
| Shares Outstanding 5 | 2.41B |
| Implied Shares Outstanding 6 | 2.41B |
| Float 8 | 2.4B |
| % Held by Insiders 1 | 0.09% |
| % Held by Institutions 1 | 72.77% |
| Shares Short (10/15/2024) 4 | 18.66M |
| Short Ratio (10/15/2024) 4 | 3.2 |
| Short % of Float (10/15/2024) 4 | 0.78% |
| Short % of Shares Outstanding (10/15/2024) 4 | 0.78% |
| Shares Short (prior month 9/13/2024) 4 | 23.03M |
Dividends & Splits
| Forward Annual Dividend Rate 4 | 4.96 |
| Forward Annual Dividend Yield 4 | 3.20% |
| Trailing Annual Dividend Rate 3 | 4.86 |
| Trailing Annual Dividend Yield 3 | 3.13% |
| 5 Year Average Dividend Yield 4 | 2.71 |
| Payout Ratio 4 | 80.33% |
| Dividend Date 3 | 12/10/2024 |
| Ex-Dividend Date 4 | 11/26/2024 |
| Last Split Factor 2 | 2:1 |
| Last Split Date 3 | 6/13/2001 |
Footnotes
- 1 Data provided by Refinitiv.
- 2 Data provided by EDGAR Online.
- 3 Data derived from multiple sources or calculated by Yahoo Finance.
- 4 Data provided by Morningstar, Inc.
- 5 Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.
- 6 Implied Shares Outstanding of common equity, assuming the conversion of all convertible subsidiary equity into common.
- 7 EBITDA is calculated by S&P Global Market Intelligence using methodology that may differ from that used by a company in its reporting.
- 8 A company’s float is a measure of the number of shares available for trading by the public. It’s calculated by taking the number of issued and outstanding shares minus any restricted stock, which may not be publicly traded.
“The financial figures mentioned in this analysis are derived from Yahoo Finance for accuracy and reliability.”
Factors That Affect Johnson & Johnson Share Price India 2025
1) Earnings Reports and Financial Performance
- Revenue Growth: The quarterly earnings reports of J&J have a significant impact on the company’s share price. Positive investor sentiment and stock price appreciation are often fueled by robust revenue growth from the company’s pharmaceutical and medical device segments. Conversely, stock price swings may result from any indications of slowing growth in important sectors.
- Profit Margins: Investors keep a careful eye on Johnson & Johnson Share Price India 2025 profit margins, just like they do for any major company. High margins increase the company’s overall valuation, especially in the pharmaceutical industry (because of patent-protected drugs).
2) Product Launches and Innovations
- The company’s stock price is significantly influenced by its capacity for innovation, particularly in its pharmaceutical division. Successful product launches frequently lead to notable increases in share prices, especially in fields with high demand like neuroscience, immunology, and oncology.
- For instance, investor optimism may be sparked by the approval of novel medications or improvements in surgical technology under its medical devices segment.
3) Legal and Regulatory Challenges
- Lawsuits and Settlements: Over the years, Johnson & Johnson has been embroiled in several high-profile lawsuits, most notably those involving its medical devices, opioid products, and baby powder made with talc. The stock price may fluctuate temporarily as a result of these legal problems, particularly if the business is hit with sizable settlements or unfavorable court decisions.
- FDA and Regulatory Approvals: Obtaining regulatory approvals from the U.S. Food and Drug Administration (FDA) and other international organizations is essential to Johnson & Johnson Share Price India 2025 operations as a healthcare company. Stock performance may suffer if approvals are denied or delayed.
4) Global Market Trends and Demographics
- Global demographic trends, such as the aging of populations in developed nations and the rise in healthcare demands in emerging markets, are linked to the demand for healthcare products. Companies like Johnson & Johnson Share Price India 2025, which supply vital healthcare products all over the world, are typically favored by these trends.
- J&J’s stock price may also be impacted by modifications to insurance policies, healthcare regulations, or worldwide economic conditions. For example, the company’s profitability may be impacted by government initiatives pertaining to health insurance reforms or drug prices in the United States.
5) Dividend History and Stock Buybacks
- Dividend Yield: Because of its consistent dividend payments, J&J is well-known for drawing in income-conscious investors. The company is a member of the exclusive Dividend Kings club, which is made up of businesses that have raised dividends continuously for more than 50 years.It has done so for more than 50 years.
- Stock Buybacks: J&J has implemented stock buyback programs in addition to dividends, which lower the number of outstanding shares and increase earnings per share (EPS), potentially bolstering the share price.
Historical Performance of Johnson & Johnson Share Price
In the past, Johnson & Johnson Share Price India has shown excellent performance, and its stock price has increased steadily over time. Because of the stability of the healthcare industry, the company’s stock has held up well during market downturns.
- Long-term Growth: The share price of J&J has produced significant returns for its shareholders over the last few decades. The company’s stock price has remained relatively stable and appealing to long-term investors due to its conservative business strategy, which emphasizes consistent revenue growth, robust cash flow, and a diverse product portfolio.
- Resilience During Market Downturns: Similar to numerous healthcare organizations, J&J has demonstrated resilience in times of economic downturn or recession. Many investors view J&J as a “defensive stock” because the healthcare sector is typically less susceptible to economic cycles than other industries.
For instance, J&J’s diversified business strategy has helped reduce risks even in the face of difficulties like product recalls or lawsuits, guaranteeing that the company’s stock price won’t see sharp long-term drops.
Conclusion
One of the most reputable and trustworthy businesses in the healthcare industry is still Johnson & Johnson Share Price India 2025. It is an appealing option for investors due to its innovative products, diversified portfolio, and steady growth and dividend history.
Numerous factors, such as the company’s financial performance, new product developments, legal troubles, regulatory changes, and general economic conditions, can affect the share price of the company. Nonetheless, Johnson & Johnson Share Price India 2025 long-term growth potential and reputation for resiliency continue to make it a desirable investment, especially for individuals looking for stability in the healthcare industry.
It’s crucial for anyone thinking about investing in Johnson & Johnson Share Price India 2025 to monitor the company’s particular performance metrics in addition to the general market trends. With its steady dividend payments, solid financials, and expanding product line, Johnson & Johnson Share Price India is probably going to be a mainstay in the healthcare sector and in investors’ portfolios for a long time to come.
1 thought on “Johnson & Johnson Share Price India 2025”